Case Study: Development and Validation of Clinical ctDNA Cancer Assays | GenomeWeb
May 09, 2017
Sponsored by
SeraCare

Case Study: Development and Validation of Clinical ctDNA Cancer Assays

GenomeWebinar

 Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine 

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

If you are a clinical laboratory that is currently running or about to begin offering NGS-based clinical genomics testing and want to know how other labs have addressed specific validation and daily implementation challenges, this webinar series is for you!

Labs looking to implement NGS diagnostics face a number of regulatory challenges. These tests currently fall under the Clinical Laboratory Improvement Amendment guidelines as laboratory developed tests and lack specific validation guidelines and global performance standards. Moreover, these assays feature complex workflows comprised of hardware, wetware, and software from multiple vendors assembled — far different from more standardized approaches that fall under the Food and Drug Administration's guidelines for in vitro diagnostics.

In this webinar, Tony Godfrey of the Boston University School of Medicine will discuss how his lab is developing and validating clinical circulating tumor DNA assays. Webinar attendees will be able to ask questions during a live Q&A session.

Sponsored by

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.